把肿瘤变成“原位疫苗”!Replimune(REPL.US)溶瘤病毒闯过FDA,PD-1耐药黑色素瘤迎来新一代免疫重启方案

智通财经
Aug 07
【把肿瘤变成“原位疫苗”!Replimune(REPL.US)溶瘤病毒闯过FDA,PD-1耐药黑色素瘤迎来新一代免疫重启方案】智通财经APP获悉,美国药物监管机构正式批准了新锐肿瘤免疫生物科技公司Replimune Group Inc.(REPL.US)的一款黑色素瘤治疗药物,用于治疗接受免疫疗法后仍未获益的患者——对于这家新锐医药公司而言,这是一次重大胜利,此前该公司前两次寻求该药获批均遭监管机构拒绝。FDA表示,该药物是在91名晚期黑色素瘤患者的单臂试验中获得批准的,其中24%的患者肿瘤缩小。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10